| Calcium-based phosphate binder, by DOPPS country and cross-section |
| N Ptnts | Wgtd % | Total N | ||
|---|---|---|---|---|
| DOPPS Country | DOPPS Cross-section | 6,046 | 66.3% | 9,117 |
| All | DOPPS 2(2002) | |||
| DOPPS 3(2006) | 4,831 | 56.5% | 8,552 | |
| DOPPS 3(2007) | 4,467 | 58.1% | 7,672 | |
| AusNZ | DOPPS 2(2002) | 405 | 79.7% | 513 |
| DOPPS 3(2006) | 397 | 75.7% | 527 | |
| DOPPS 3(2007) | 384 | 80.4% | 486 | |
| Belgium | DOPPS 2(2002) | 470 | 87.2% | 538 |
| DOPPS 3(2006) | 336 | 65.1% | 509 | |
| DOPPS 3(2007) | 288 | 68.9% | 420 | |
| Canada | DOPPS 2(2002) | 499 | 83.3% | 601 |
| DOPPS 3(2006) | 422 | 77.3% | 551 | |
| DOPPS 3(2007) | 353 | 78.2% | 445 | |
| France | DOPPS 2(2002) | 341 | 64.4% | 528 |
| DOPPS 3(2006) | 257 | 47.3% | 551 | |
| DOPPS 3(2007) | 311 | 56.2% | 543 | |
| Germany | DOPPS 2(2002) | 331 | 58.9% | 571 |
| DOPPS 3(2006) | 317 | 55.0% | 583 | |
| DOPPS 3(2007) | 375 | 60.0% | 623 | |
| Italy | DOPPS 2(2002) | 219 | 37.8% | 576 |
| DOPPS 3(2006) | 145 | 27.2% | 533 | |
| DOPPS 3(2007) | 175 | 31.8% | 542 | |
| Japan | DOPPS 2(2002) | 1,365 | 75.5% | 1,805 |
| DOPPS 3(2006) | 1,258 | 68.7% | 1,832 | |
| DOPPS 3(2007) | 1,233 | 66.0% | 1,867 | |
| Spain | DOPPS 2(2002) | 439 | 71.5% | 613 |
| DOPPS 3(2006) | 292 | 43.9% | 666 | |
| DOPPS 3(2007) | 271 | 49.1% | 555 | |
| Sweden | DOPPS 2(2002) | 351 | 63.9% | 547 |
| DOPPS 3(2006) | 252 | 46.4% | 542 | |
| DOPPS 3(2007) | 247 | 47.8% | 511 | |
| UK | DOPPS 2(2002) | 266 | 47.0% | 565 |
| DOPPS 3(2006) | 213 | 48.3% | 445 | |
| DOPPS 3(2007) | 180 | 52.2% | 351 | |
| US | DOPPS 2(2002) | 1,360 | 60.1% | 2,260 |
| DOPPS 3(2006) | 942 | 51.3% | 1,813 | |
| DOPPS 3(2007) | 650 | 48.6% | 1,329 | |
| Medications reported as prescribed (not necessarily taken) in previous four months, among all patients |
Please see additional methodological information in the Data Sources and Methods section.